Journal of Bone Oncology最新文献

{"title":"Doxorubicin induces bone loss and modifies multiple cell populations in vivo – Implications for modelling of bone metastasis","authors":"Veli Kaan Aydin ,&nbsp;Lubaid Saleh ,&nbsp;Penelope Dawn Ottewell ,&nbsp;Ingunn Holen","doi":"10.1016/j.jbo.2025.100736","DOIUrl":"10.1016/j.jbo.2025.100736","url":null,"abstract":"<div><div>Doxorubicin (DOX), commonly used to treat breast cancer, is associated with cardiotoxicity and has negative effects on other organ systems, including the skeleton. DOX-induced bone damage has been demonstrated in murine models; however, results are conflicting due to the use of different doses, schedules, and rat/mouse strains. As DOX is used to limit tumour progression in models of skeletal metastasis, it is paramount to determine how the agent affects the bone microenvironment in the relevant mouse strains, to enable correct interpretation of DOX effects in tumour studies. We have therefore investigated the effects of DOX on bone structure and a range of bone and bone marrow cell populations, comparing immunocompetent and immunocompromised mice.</div><div>Groups of 7-week-old female BALB/c and BALB/c Nude mice were treated with either saline (control), 4 or 6 mg/kg DOX weekly for four weeks. Effects on bone volume and structure was determined using <em>ex vivo</em> µCT, a panel of bone marrow cell populations were quantified by flow cytometry and osteoblast/osteoclast numbers were assessed using bone histomorphometry.</div><div>DOX caused trabecular bone loss, with immunocompetent BALB/c mice being more sensitive to DOX than the immunocompromised BALB/c nude counterparts. The 6 mg/kg dose of DOX altered the ratio of bone marrow immune and haematopoietic cell populations in both groups, increasing the numbers of hematopoietic cells and progenitors, decreasing B cells and increasing the number of neutrophils. Bone marrow macrophage and monocyte numbers were increased following DOX treatment in BALB/c nude mice only. Our data demonstrate that DOX impacts a number of cell types in the bone microenvironment, highlighting the importance of considering treatment-induced bone effects when using DOX in models of bone metastasis.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"56 ","pages":"Article 100736"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145798385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life use of bone-targeting agents for bone metastases in France between 2009 and 2018: Results of the OPTIMOS study","authors":"Cyrille B. Confavreux ,&nbsp;Béatrice Bouvard ,&nbsp;Nicolas Girard ,&nbsp;Pauline Bosco-Levy ,&nbsp;Clarisse Marchal ,&nbsp;Maeva Nolin ,&nbsp;Eric Lehmann ,&nbsp;Gaelle Desameric ,&nbsp;Manon Belhassen","doi":"10.1016/j.jbo.2025.100738","DOIUrl":"10.1016/j.jbo.2025.100738","url":null,"abstract":"<div><h3>Aim</h3><div>To determine the use of bone-targeting agents (BTAs) in clinical practice in France and the occurrence of skeletal-related events (SREs) in cancer patients with bone metastases.</div></div><div><h3>Methods</h3><div>This study analysed data, recorded prospectively in a French National Health Insurance database, for patients who had a first diagnosis of bone metastases between 2009 and 2018.</div></div><div><h3>Results</h3><div>A total of 6,663 patients were analysed (mean age 69.7 ± 13.2 years, 53.2 % male) corresponding to 2,363 bone metastases only patients and 4,300 patients with SREs at inclusion. The most frequent primary cancers were breast (15.8 %), prostate (13.4 %), lung (12.6 %) and digestive cancer (10.6 %). Six-hundred and twenty-one patients (9.3 %) were treated with BTAs (52.7 % with denosumab). Median [IQR] time between inclusion and BTA initiation was similar with denosumab (3.3 months [1.2–7.9]) and bisphosphonates (3.3 months [1.2–8.7]). Patients with a SRE at inclusion and early BTA initiation (≤3 months) had a significative lower incidence of a second SRE at 12 months than those with late initiation (13.6 % [95 %CI: 8.1–20.4] vs. 21.6 % [14.8–29.2] respectively; p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>BTAs are underused in bone metastases patients in France. There is an urgent need to optimise bone metastases management in accordance with ESMO 2020 guidelines.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"56 ","pages":"Article 100738"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145939112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot study of separation surgery with intraoperative radiotherapy (IORT) for spine metastasis","authors":"Baiyi Liu ,&nbsp;Dongsheng Wang ,&nbsp;Jian Zhang ,&nbsp;Bo Huang ,&nbsp;Mingying Geng ,&nbsp;Peng Liu ,&nbsp;Yaoyao Liu","doi":"10.1016/j.jbo.2025.100737","DOIUrl":"10.1016/j.jbo.2025.100737","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to introduce a novel modified separation surgery combined with intraoperative radiotherapy (MSS-IORT) treatment strategy for spinal metastasis and evaluate its efficacy and safety.</div></div><div><h3>Methods</h3><div>A prospective study was conducted from January 2023 to June 2024. Patients with spinal metastasis exhibiting epidural spinal cord compression (ESCC) ≥ 2 grades and spinal instability neoplastic score (SINS) ≥ 7 were enrolled and underwent MSS-IORT. During the procedure, a dose of 8–10 Gy of IORT was administered to the tumor-invaded vertebrae segments during modified separation surgery. Pain intensity was assessed using the visual analog scale (VAS) preoperatively and at 1 week, 3 months, 6 months, and 12 months postoperatively. Neurological function was evaluated <em>via</em> the Frankel grade system, and functional status was measured using the Karnofsky performance scale (KPS) preoperatively and at 3, 6, and 12 months after surgery. Local control was evaluated based on X-ray, CT, or MRI examination. Survival time and perioperative complications were also documented.</div></div><div><h3>Results</h3><div>A total of 38 patients (median age: 60 years) with 46 involved vertebrae were treated with MSS-IORT. The mean operation time was 277.5 min, and the mean blood loss was 750 ml. After a mean follow-up of 174.5 days, the VAS score decreased significantly postoperatively and continued to decline over time. The KPS score increased significantly at 6 and 12 months, and the Frankel grade significantly improved at 12 months. Local control failure occurred in 3 patients, and 13 experienced adverse events without IORT.</div></div><div><h3>Conclusion</h3><div>The MSS-IORT strategy demonstrates both safety and efficacy, representing a promising treatment option for spine metastases, particularly in patients with ESCC grades ≥ 2 and SINS ≥ 7.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"56 ","pages":"Article 100737"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145939114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mri-based habitat and peritumoral radiomics for predicting the proliferative activity of stromal cells in giant cell tumor of bone","authors":"Jie Xia ,&nbsp;Kunming Jiang ,&nbsp;Jinyi Zhou ,&nbsp;Lei Cao ,&nbsp;Fan Xiao ,&nbsp;Jingxuan Jiang","doi":"10.1016/j.jbo.2025.100733","DOIUrl":"10.1016/j.jbo.2025.100733","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aims to explore the feasibility of MRI-based habitat and peritumoral radiomics for predicting the proliferative activity of stromal cells in giant cell tumor of bone (GCTB)<strong>.</strong></div></div><div><h3>Material and methods</h3><div>A retrospective study was performed on 133 patients<!--> <!-->(102 in training cohort and 31 in validation cohort) diagnosed with GCTB<!--> <!-->from four centers. The tumor was meticulously segmented into three distinct habitat subregions using K-means clustering, incorporating a 1-pixel peritumoral expansion to capture the microenvironments surrounding the tumor. After feature extraction and selection, habitat, intratumoral and peritumoral models integrating three different machine learning classifiers were constructed respectively to identify GCTB patients with high and low proliferation. The performance of the models was assessed by receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). SHAP analysis was utilized to enhance model interpretability.</div></div><div><h3>Results</h3><div>Among the eligible patients, 43 (32.3 %) diagnosed with high proliferative activity of stromal cells in GCTB by pathological diagnosis. Among all models tested in the validation cohort, the Logistic Regression (LR) algorithm for habitat model exhibited superior performance in the validation cohort (AUC: 0.956, 95 % CI: 0.887–1.000). The calibration curves and DCA exhibited fit for the habitat model while providing great clinical net benefit.</div></div><div><h3>Conclusion</h3><div>MRI-based habitat radiomics had the potential to predict the proliferative activity of stromal cells in GCTB. This model may help determine optimal treatment strategies and improve patient outcomes.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"56 ","pages":"Article 100733"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145749334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Soft tissue recurrence in giant cell tumor of Bone: A comprehensive review of pathogenesis, imaging features, and clinical management","authors":"Khodamorad Jamshidi ,&nbsp;Hamed Naghizadeh ,&nbsp;Sadegh Saberi ,&nbsp;Farshad Zand Rahimi ,&nbsp;Aidin Arabzadeh ,&nbsp;Seyyed Saeed Khabiri","doi":"10.1016/j.jbo.2025.100725","DOIUrl":"10.1016/j.jbo.2025.100725","url":null,"abstract":"<div><h3>Background</h3><div>Giant cell tumor of bone (GCTB) is a benign but locally aggressive neoplasm with a high risk of recurrence. Among its patterns of relapse, soft-tissue recurrence (STR) is an uncommon but clinically significant entity, often presenting as ossified or non-ossified perilesional nodules. Despite its rarity, STR poses diagnostic and therapeutic challenges that require clarification.</div></div><div><h3>Methods</h3><div>A comprehensive literature review was performed across PubMed, Embase, and Google Scholar from 1980 through January 2025, focusing on the epidemiology, pathogenesis, imaging features, histopathology, management, and outcomes of STR in GCTB. Case reports, series, and retrospective studies explicitly distinguishing STR from intraosseous recurrence were included, and findings were synthesized narratively.</div></div><div><h3>Results</h3><div>STR occurs in approximately 2–3 % of GCTB cases, typically within 6–12 months after surgery. Major risk factors include curettage procedures, pathological fractures, cortical breaches, and unrecognized microscopic soft-tissue extension. Imaging reveals three distinct patterns: peripheral “eggshell” ossification, central nodular calcification, and purely soft-tissue lesions. Histology mirrors primary GCTB, often with osteogenic metaplasia, while molecular testing confirms retention of H3F3A mutations. Surgical excision with clear margins remains the mainstay of treatment, yielding excellent functional outcomes. However, up to 60 % of patients experience multiple recurrences, highlighting the need for vigilant surveillance. Systemic agents such as denosumab or bisphosphonates remain investigational, and radiotherapy is generally contraindicated due to malignant transformation risk.</div></div><div><h3>Conclusion</h3><div>STR represents a rare but distinct subset of GCTB recurrences. Awareness of risk factors, early imaging-based detection, and complete surgical excision are critical for optimal outcomes. Further multicenter studies are required to define surveillance protocols, validate molecular predictors, and clarify the role of systemic therapy in this challenging condition.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"55 ","pages":"Article 100725"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145520107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"hMSCs-derived exosomal MIR17HG promotes follicular helper T cell differentiation and osteosarcoma progression via the miR-372-3p/BCL6 axis","authors":"Jin Qi ,&nbsp;Gang Xue ,&nbsp;Baomin Wu ,&nbsp;Peng Zhu ,&nbsp;Yapeng Wang","doi":"10.1016/j.jbo.2025.100726","DOIUrl":"10.1016/j.jbo.2025.100726","url":null,"abstract":"<div><h3>Background</h3><div>Osteosarcoma (OS) is a life-threatening malignancy in children and adolescents, with limited treatment options for resistant or metastatic disease. Exosomes derived from hMSCs regulate tumor immunity by transporting molecules such as long non-coding RNA (lncRNA). The lncRNA MIR17HG is known to promote OS progression, yet its role in regulating T follicular helper (Tfh) cell differentiation in OS is unclear. This study is the first to systematically explore how MIR17HG influences Tfh cell differentiation, activation, and OS cell proliferation via the miR-372-3p/BCL6 signaling cascade.</div></div><div><h3>Methods</h3><div>Exosomes were extracted from hMSCs using differential centrifugation. Characterization of hMSCs-derived exosomes was conducted by TEM, NTA and western blotting. The expression of MIR17HG, BCL6 and PD-1 was determined by qRT‒PCR or western blotting. The differentiation and activation of Tfh cells, as well as OS apoptosis, were assessed through flow cytometry. OS cell viability was determined by a CCK-8 assay. The effect of hMSCs-Exo-MIR17HG on tumors was assessed in an MG63-derived xenograft mouse model. The expression of Ki67 was examined via IHC. RNA immunoprecipitation was performed to validate the interaction between MIR17HG and miR-372-3p. A dual-luciferase reporter assay was performed to explore the correlation between miR-372-3p and BCL6.</div></div><div><h3>Results</h3><div>The lncRNA MIR17HG was expressed in hMSCs-derived exosomes and upregulated by overexpression. hMSCs-Exo or hMSCs-Exo-MIR17HG promoted the differentiation and activation of Tfh cells, accompanied by increased PD-1 and BCL6 expression in CD4⁺ T cells, which enhanced OS cell proliferation. Furthermore, hMSCs-Exo-MIR17HG exerted a tumor-promoting effect in a CDX mouse model. Mechanistically, the effects driven by MIR17HG were abolished by miR-372-3p overexpression, and BCL6 was identified as a direct functional target of miR-372-3p.</div></div><div><h3>Conclusion</h3><div>These findings demonstrate that exosomal MIR17HG derived from hMSCs drives the differentiation of follicular helper T cells and the progression of OS via the miR-372-3p/BCL6 axis.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"55 ","pages":"Article 100726"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145568330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benign and malignant bone lesion diagnosis based on self-supervised and radiomics fusion using SPECT/CT images","authors":"Weiming Xie ,&nbsp;Xiaozhou Bai ,&nbsp;Miao Liu ,&nbsp;Haonan Shangguan ,&nbsp;Ying Zhan ,&nbsp;Xiaodan Wu ,&nbsp;Yingxin Dai ,&nbsp;Yusong Pei ,&nbsp;Guoxu Zhang ,&nbsp;Zhiguo Wang ,&nbsp;Zhaomin Yao","doi":"10.1016/j.jbo.2025.100723","DOIUrl":"10.1016/j.jbo.2025.100723","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aims to improve the diagnostic accuracy of SPECT/CT imaging in distinguishing benign from malignant bone lesions by integrating self-supervised deep learning and radiomics, reducing subjectivity in traditional image interpretation for more reliable clinical decision-making.</div></div><div><h3>Methods</h3><div>We developed a multi-scale, multi-modal framework combining radiomics with self-supervised learning. The novel SPECT-guided model, SPARC-Net, uses functional SPECT data as semantic priors to extract discriminative features from CT scans without manual annotations. Deep features from SPARC-Net were fused with radiomics to form a unified representation. The model was trained and validated on 741 confirmed bone lesion cases using five-fold cross-validation, with interpretability assessed via Grad-CAM.</div></div><div><h3>Results</h3><div>The fused model achieved 82.3 % accuracy, 0.890 AUC, 72.3 % F1 score, 79.3 % precision, 66.6 % sensitivity, and 90.7 % specificity, outperforming single-modality models. Grad-CAM confirmed the model focused on metabolically active regions identified by SPECT.</div></div><div><h3>Conclusion</h3><div>SPARC-Net, integrating SPECT-guided self-supervised learning with CT-based radiomics, improves classification of benign and malignant lesions, enhancing the accuracy, robustness, and interpretability of SPECT/CT imaging for bone tumor diagnosis.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"55 ","pages":"Article 100723"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145466325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal deep learning for bone tumor diagnosis with clinical imaging, pathology, and blood biomarkers","authors":"Hang Sang ,&nbsp;Tao Lin ,&nbsp;Lincong Luo ,&nbsp;Mingrui Liu ,&nbsp;Jiaying Li ,&nbsp;Xiang Luo ,&nbsp;Jianlin Shen ,&nbsp;Shizhen Zhong ,&nbsp;Lin Xu ,&nbsp;Wenhua Huang","doi":"10.1016/j.jbo.2025.100718","DOIUrl":"10.1016/j.jbo.2025.100718","url":null,"abstract":"<div><div>Accurate classification of bone tumors as benign, malignant, or intermediate is crucial for patient treatment decisions. Misclassification may result in overtreatment of benign cases or delayed intervention for aggressive tumors, significantly impacting patient prognosis. However, current methods rely heavily on single-modality imaging analysis, making it difficult to handle variable lesion locations and complex cancer types. To address these limitations, we propose a novel multimodal deep learning framework that integrates clinical images, pathological slices, and blood biomarkers for automated bone tumor detection and three-class classification. The framework operates in two stages: first, a YOLOv5-based detection model localizes tumor regions on clinical images. Next, a classification model utilizes ResNet to extract deep features from both the clinical images and pathological slices, while abnormal blood biomarkers are transformed into descriptive text by a large language model and subsequently encoded into semantic features using BioBERT. Finally, features from all three modalities are integrated via a fusion module to capture complementary information and enable accurate tumor classification. The evaluation was performed using two distinct datasets: a clinical imaging dataset for bone tumor detection, and a separate multi-modal cohort comprising clinical imaging, pathology, and blood biomarkers for tumor classification. The detection model demonstrated strong localization capabilities, achieving a test [email protected] of 0.7925. For the classification task, ablation studies validated the complementary contribution of each modality. Notably, our multimodal fusion approach outperformed unimodal baselines, attaining a macro-average precision of 0.9056, F1-score of 0.8736, and AUC of 0.9759 in tumor classification—outperforming existing models.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"55 ","pages":"Article 100718"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145364074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma − a single center, retrospective imaging analysis on 119 patients","authors":"Evangelos Terpos ,&nbsp;Vassilis Koutoulidis ,&nbsp;Ioannis Ntanasis-Stathopoulos ,&nbsp;Stylianos Mavropoulos-Papoudas ,&nbsp;Maria Douka ,&nbsp;Maria Gavriatopoulou ,&nbsp;Panagiotis Malandrakis ,&nbsp;Vasiliki Spiliopoulou ,&nbsp;Foteini Theodorakakou ,&nbsp;Despina Fotiou ,&nbsp;Magdalini Migkou ,&nbsp;Nikolaos Kanellias ,&nbsp;Evangelos Eleutherakis-Papaiakovou ,&nbsp;Efstathios Kastritis ,&nbsp;Lia-Angela Moulopoulos ,&nbsp;Meletios A Dimopoulos","doi":"10.1016/j.jbo.2025.100720","DOIUrl":"10.1016/j.jbo.2025.100720","url":null,"abstract":"<div><h3>Background</h3><div>Multiple myeloma (MM) frequently presents with myeloma bone disease (MBD), manifesting as osteolytic lesions and skeletal-related events (SREs), significantly impairing quality of life and increasing morbidity. Whole-body low-dose computed tomography (WBLDCT) has become the standard for assessing bone involvement at diagnosis, but its prognostic significance remains unclear. The aim of this study was to evaluate the burden of MBD in newly diagnosed MM patients using WBLDCT and examined associations between imaging characteristics and survival outcomes.</div></div><div><h3>Methods</h3><div>In this retrospective, single center, analysis of 119 MM patients, WBLDCT was performed at diagnosis prior to treatment initiation. Imaging findings, including vertebral compression fractures (VCFs), lesion number, cortical destruction, and appendicular skeleton medullary cavity (ASMC) patterns, were recorded. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier curves and Cox regression models.</div></div><div><h3>Results</h3><div>VCFs were significantly associated with inferior PFS (18.1 vs. 33.6 months; p = 0.013) and OS (51.5 months vs. not reached; p = 0.023) in univariate analyses. However, in multivariable models, no imaging parameter, including VCFs, retained independent prognostic significance. Other imaging variables (lesion count, ASMC subtype, cortical destruction) were not predictive of outcomes.</div></div><div><h3>Conclusions</h3><div>While VCFs identified on WBLDCT correlate with poor outcomes in univariate analysis, they do not serve as independent prognostic markers when adjusting for established clinical factors. These findings suggest that in the era of novel anti-myeloma therapeutics, the bone disease burden at diagnosis may not impact prognosis significantly.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"55 ","pages":"Article 100720"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145417510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment and comprehensive characterization of a subline with highly bone-metastatic propensity derived from the lung adenocarcinoma A549 cell line","authors":"Yujian Xu ,&nbsp;Yahan Qin ,&nbsp;Wenjun Chai ,&nbsp;Ke Xue ,&nbsp;Xiaoli Liu ,&nbsp;Jing Li ,&nbsp;Yue Cao ,&nbsp;Lei Sun ,&nbsp;Hongyu Pan ,&nbsp;Mingxia Yan","doi":"10.1016/j.jbo.2025.100719","DOIUrl":"10.1016/j.jbo.2025.100719","url":null,"abstract":"<div><div>Bone metastasis is a major cause of mortality in lung adenocarcinoma, but the mechanisms remain poorly understood. Here, we established a highly bone-metastatic subline, A549-BM5, from the A549 cell line through five rounds of <em>in vivo</em> selection. A549-BM5 cells exhibited enhanced migration and invasion, and preferentially colonized specific skeletal sites in mouse models. In the bone microenvironment, they promoted the recruitment and differentiation of osteoblasts and osteoclasts, disrupting bone homeostasis. Transcriptomic and proteomic profiling revealed dysregulation in pathways such as EMT, adhesion, and bone morphogenesis. We further applied a random forest model to identify potential therapeutic targets associated with bone metastasis. Compared to existing A549-based models, A549-BM5 offers earlier metastasis onset, stable bone tropism, and broader interaction with the bone niche. This model provides a valuable platform for mechanistic studies and therapeutic development targeting lung cancer bone metastasis.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"55 ","pages":"Article 100719"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145364075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}